CN105218647A - VEGFR2 blocker polypeptide and application thereof - Google Patents
VEGFR2 blocker polypeptide and application thereof Download PDFInfo
- Publication number
- CN105218647A CN105218647A CN201510711189.XA CN201510711189A CN105218647A CN 105218647 A CN105218647 A CN 105218647A CN 201510711189 A CN201510711189 A CN 201510711189A CN 105218647 A CN105218647 A CN 105218647A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- vegfr2
- ovarian cancer
- present
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to pharmaceutical field, be specifically related to that there is suppression interleukin-33, the polypeptide of ovarian cancer can be treated.Its sequence is RGDVKHHINFPPSTMPPMYIGC is brand-new sequence, in the present invention can blocking VEGF in conjunction with VEGFR2, and then affect VEGF downstream signal conduction, realize antitumor object.The present invention adopts the modelling verification of ovarian cancer inside and outside, and it can effective Tumor suppression propagation, and growth, can as effective antitumour drug candidate, for Development of New Generation antitumor drug provides new selection.
Description
Technical field:
The present invention relates to pharmaceutical field, be specifically related to the combination for blocking VEGF R2, the VEGFR2 blocker polypeptide for the treatment of ovarian cancer.
Background technology:
Malignant tumor of ovary is one of common malignant tumour of female sex organ, and sickness rate is only second to cervical cancer and carcinoma of uterine body and arranges the 3rd, residence.But ovarian epithelium mortality of carcinoma accounts for the first place of all kinds of gynecological tumor, serious threat is caused to women's life.Because the fetal development of ovary, anatomic tissue and endocrine function are more complicated, early symptom is not true to type, the organization type of preoperative identification of ovarian tumour and good pernicious quite difficulty.The most common with epithelial cancer in malignant tumor of ovary, be secondly malignant germ cell tumors.What find in epithelial ovarian cancer corrective surgery that tumour is confined to ovary only accounts for 30%, and great majority are diffused into uterus, bilateral annex, greater omentum and each organ of pelvic cavity.Current methods for the treatment of has:. operative treatment, chemotherapy, radiotherapy etc.Because malignant tumor of ovary especially epithelial cancer spreads very early, during operation, majority of cases can not remove focus, and the effect of radiotherapy and application also very limited, therefore systemic chemotherapy is an important auxiliary treating method.Especially malignant germ cell tumors, specification chemotherapy can significantly improve survival.Some end-stage patients, after chemotherapy, lump can reduce, and creates favorable conditions for satisfaction during operation subtracts knurl.But antitumor drug existence makes patient's immunocompromised, the side effects such as hair loss, vomiting, weight loss, limit its application.How to find efficient, the low ovarian cancer resistance medicament of side effect becomes a difficult problem urgently to be resolved hurrily.
The growth of tumour be unable to do without the new life of blood vessel and the stimulation of various somatomedin and release, and Tumor suppression new vessel may become a kind of effective ways for the treatment of tumour.Vascular endothelial growth factor (Vascularendothelialgrowthfactor, VEGF) high expression level and the formation of noumenal tumour and shift closely related, VEGF by with the specific receptors (Vascularendothelialgrowthfactorreceptor on endothelial cellular membrane, VEGFR) combine in the born of the same parents of activation signal conduction and have high expression level, and expression level is very low in the one-tenth person of health does not even express.VEGFR2 can promote vascular endothelial cell proliferation, migration and increase capillary permeability.The mitotic division of tumor vascular endothelial cell and the perviousness of tumor-microvessel are mainly occurred by the interaction of VEGF and VEGFR2.Therefore, VEGFR2 blocker, can effectively suppress VEGF and VEGFR2 to combine, and then effectively Tumor suppression is bred, and migration reaches the object of Tumor suppression growth.
Summary of the invention:
The invention provides brand-new sequence, this sequence blocking VEGF R2, in conjunction with VEGF, has good curative effect to ovarian cancer.
Technical scheme
VEGFR2 blocker polypeptide, is characterized in that its sequence is RGDVKHHINFPPSTMPPMYIGC.
A kind of pharmaceutical composition, is characterized in that it comprises polypeptide and more than one pharmaceutically acceptable vehicle, weighting agent, tackiness agent, lubricant, disintegrating agent or stablizer as claimed in claim 1.
Described pharmaceutical composition, is characterized in that, described composition is injection.
Described VEGFR2 blocker polypeptide, is characterized in that effective dose is 10mg/kg.
Described VEGFR2 blocker polypeptide, the application in treatment ovarian cancer.
Beneficial outcomes:
VEGFR2 blocker polypeptide 1 sequence RGDVKHHINFPPSTMPPMYIGC in the present invention, can blocking VEGF in conjunction with VEGFR2, and then affect VEGF downstream signal conduction, realize antitumor object.The present invention adopts the modelling verification of ovarian cancer inside and outside, and it can effective Tumor suppression propagation, and growth, can as effective antitumour drug candidate, for Development of New Generation antitumor drug provides new selection.
Embodiment
The present invention relates to polypeptide (RGDVKHHINFPPSTMPPMYIGC) to be synthesized by gill biochemistry (Shanghai).Human ovarian cancer SK-OV-3 is purchased from Shanghai cell biological institute of Chinese Academy of Sciences cell bank.
Embodiment 1
The effect that VEGFR2 blocker polypeptide is bred Proliferation of Human Ovarian Cell SK-OV-3
Adopt MTT colorimetry:
1, cell cultures: abortion syndrome SK-OV-3 with containing McCoy ' the s5A substratum of 10% foetal calf serum, 37 DEG C, 5%CO2, to cultivate under saturated humidity condition, be epithelial cell type, adherent growth.Every 2 ~ 3 days with 0.25% pancreatin and 0.02%EDTA conventional digestion, 1:3 ~ 1:6 Secondary Culture.
2, by the SK-OV-3 cell of logarithmic growth, add in 96 well culture plates with 1.0 × 105, cultivate 24h, experimental port, positive drug control hole add Experimental agents VEGFR2 blocker polypeptide and the positive control medicine vincristine(VCR) of different concns respectively; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, and cultivate 48h, every hole adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula growth of tumour cell inhibiting rate=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 0.43 μM.And positive control medicine vincristine(VCR) 0.39 μM, both do not have significant difference, illustrate that polypeptide of the present invention has and suppress human ovarian cancer effect.
The inhibition test that embodiment 2VEGFR2 blocker polypeptide grows Proliferation of Human Ovarian Cell SK-OV-3 nude mouse xenograft tumor
The Proliferation of Human Ovarian Cell SK-OV-3 cell strain of taking the logarithm vegetative period, is aseptically prepared into 5 × 10
7/ ml cell suspension, is inoculated in armpit on the right side of nude mice with 0.1ml subcutaneous.With vernier caliper measurement transplanted tumor in nude mice diameter, treat that tumor growth is to 70-100mm
3after by animal random packet.Use the method measuring knurl footpath, dynamically observe the antitumous effect of tested polypeptide.The pendulous frequency of diameter of tumor is survey 1 time for every 2 days.Administering mode all adopts tail vein injection.Negative control group injection normal saline, every day 1 time; Taxol group 10mg/kg, Per-Hop behavior 1 time; RhEndostatin group 2.5mg/kg, administration every day 1 time; High, normal, basic group of polypeptide respectively with 20mg/kg, 10mg/kg, 5mg/kg, administration every day 1 time.Administration 21d.After off-test, sacrifice, operation strips knurl block and weighs.
The restraining effect that table 1 polypeptide grows Proliferation of Human Ovarian Cell SK-OV-3 nude mouse xenograft tumor
Polypeptide shows Proliferation of Human Ovarian Cell SK-OV-3 transplanted tumor in nude mice growth inhibition test result, compared with negative control group, polypeptide 20mg/kg, 10mg/kg and 5mg/kg group all has the restraining effect of pole significance to the growth of Proliferation of Human Ovarian Cell SK-OV-3 transplanted tumor.5mg/kg group is compared with positive controls taxol, and the body weight of polypeptide to laboratory animal does not have a significant effect, and has no obvious toxic side effects, and survival rate improves.
SEQUENCELISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120>VEGFR2 blocker polypeptide and application thereof
<130>
<160>1
<170>PatentInversion3.3
<210>1
<211>22
<212>PRT
<213> artificial sequence
<400>1
ArgGlyAspValLysHisHisIleAsnPheProProSerThrMetPro
151015
ProMetTyrIleGlyCys
20
Claims (5)
1.VEGFR2 blocker polypeptide, is characterized in that its sequence is RGDVKHHINFPPSTMPPMYIGC.
2. a pharmaceutical composition, is characterized in that it comprises polypeptide and more than one pharmaceutically acceptable vehicle, weighting agent, tackiness agent, lubricant, disintegrating agent or stablizer as claimed in claim 1.
3. pharmaceutical composition as claimed in claim 2, it is characterized in that, described composition is injection.
4. VEGFR2 blocker polypeptide as claimed in claim 1, is characterized in that effective dose is 10mg/kg.
5. VEGFR2 blocker polypeptide as claimed in claim 1, the application in treatment ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510711189.XA CN105218647A (en) | 2015-10-28 | 2015-10-28 | VEGFR2 blocker polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510711189.XA CN105218647A (en) | 2015-10-28 | 2015-10-28 | VEGFR2 blocker polypeptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105218647A true CN105218647A (en) | 2016-01-06 |
Family
ID=54987975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510711189.XA Pending CN105218647A (en) | 2015-10-28 | 2015-10-28 | VEGFR2 blocker polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105218647A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111620939A (en) * | 2019-10-25 | 2020-09-04 | 南京市妇幼保健院 | Polypeptide ZYX for treating or assisting in treating ovarian cancer36-58 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145161A (en) * | 2011-04-07 | 2011-08-10 | 中国药科大学 | Application of integrin blocking agent in preparing medicament for treating tumors |
| CN102488890A (en) * | 2011-12-27 | 2012-06-13 | 中国药科大学 | Application of integrin blocker polypeptide AP25 in preparation of medicines for treating tumor |
| CN102850443A (en) * | 2011-12-27 | 2013-01-02 | 中国药科大学 | Integrin blocker polypeptides and application thereof |
| CN104045717A (en) * | 2014-07-08 | 2014-09-17 | 国家纳米科学中心 | Tumor vessel blocker polypeptide, gene, expression vector and application thereof |
-
2015
- 2015-10-28 CN CN201510711189.XA patent/CN105218647A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145161A (en) * | 2011-04-07 | 2011-08-10 | 中国药科大学 | Application of integrin blocking agent in preparing medicament for treating tumors |
| CN102488890A (en) * | 2011-12-27 | 2012-06-13 | 中国药科大学 | Application of integrin blocker polypeptide AP25 in preparation of medicines for treating tumor |
| CN102850443A (en) * | 2011-12-27 | 2013-01-02 | 中国药科大学 | Integrin blocker polypeptides and application thereof |
| CN104045717A (en) * | 2014-07-08 | 2014-09-17 | 国家纳米科学中心 | Tumor vessel blocker polypeptide, gene, expression vector and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111620939A (en) * | 2019-10-25 | 2020-09-04 | 南京市妇幼保健院 | Polypeptide ZYX for treating or assisting in treating ovarian cancer36-58 |
| CN111620939B (en) * | 2019-10-25 | 2021-01-01 | 南京市妇幼保健院 | Polypeptide ZYX for treating or assisting in treating ovarian cancer36-58 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuang et al. | Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| Lv et al. | Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER (+/−) breast cancer cells and action mechanisms | |
| CN103393638A (en) | Application of formononetin in preparing medicine for treating breast cancer | |
| CN105218647A (en) | VEGFR2 blocker polypeptide and application thereof | |
| CN110123809A (en) | 5- methyl-dihydro benzofuran-application of the imidazole salt compound in pharmacy | |
| CN105797142B (en) | The tumour radiotherapy sensitizer of the inhibitor containing eEF2K | |
| CN105198965A (en) | VEGFR2 blocker polypeptide and application thereof | |
| CN104031128B (en) | A kind of interleukin-33 inhibitor polypeptide and application thereof | |
| Yagisawa et al. | Novel approach for bladder cancer treatment using sulfoquinovosylacylpropanediol as a radiosensitizer. | |
| CN104045689B (en) | A kind of about somatostatin receptor agonist polypeptide and application thereof | |
| CN104004060B (en) | Cyclin D protein inhibitor polypeptide and application thereof | |
| CN104031122B (en) | Relevant Cyclin D protein inhibitor polypeptide and application thereof | |
| CN104059130A (en) | ST2 protein inhibitor related polypeptide and application thereof | |
| CN104017055A (en) | Protein ST2 inhibitor polypeptide and application thereof | |
| CN104004058B (en) | Relevant interleukin-33 inhibitor polypeptide and application thereof | |
| CN104017056B (en) | ST2 protein inhibitor polypeptide and application thereof | |
| CN104004061B (en) | Interleukin-33 inhibitor polypeptide and application thereof | |
| Friedman | Endocrine therapy resistance in breast cancer: mechanisms and treatments | |
| CN104017053B (en) | A kind of PER2 protein agonist polypeptide and application thereof | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| Karnchanabanyong et al. | EP253/# 205 Discrepancy in diagnosis of advanced epithelial ovarian carcinoma, tubal carcinoma and primary peritoneal carcinoma prior to neoadjuvant chemotherapy | |
| Nishio et al. | 2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan | |
| Keleş | REPURPOSING OF ION CHANNEL BLOCKERS: NEW HOPE FOR BREAST CANCER METASTASIS. | |
| Erdogan | THERAPEUTIC SILENCING OF NAV1. 5 CHANNEL IN METASTATIC BREAST CANCER MODELS IN VITRO AND IN VIVO. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160106 |
|
| WD01 | Invention patent application deemed withdrawn after publication |